Praxis Data Shows Breakthrough Seizure Control Across Epilepsies
BOSTON, MA — December 8, 2025 — Praxis Precision Medicines presented compelling new clinical results at the American Epilepsy...
ADC AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BOSTON, MA — December 8, 2025 — Praxis Precision Medicines presented compelling new clinical results at the American Epilepsy...
DUBLIN, IRELAND & LONDON, UK — December 8, 2025 — Ayrmid Ltd., parent company of Gamida Cell Inc., announced...
SHANGHAI, CHINA – November 11, 2025 — Mabwell (688062.SH), an innovative biopharmaceutical company specializing in biologics for major diseases,...
Boston, November 10, 2025 — Rhythm Pharmaceuticals, Inc. has announced the presentation of four pivotal datasets at ObesityWeek® 2025,...
FOSTER CITY, Calif., November 7, 2025 — Mirum Pharmaceuticals, Inc., a biopharmaceutical company dedicated to transforming the lives of...
